Navigation Links
A Balanced Risk-Benefit Profile Will Propel Orexigen/Takeda's Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
Date:11/6/2013

BURLINGTON, Mass., Nov. 6, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that novel emerging agents will experience steady uptake owing to the high prevalence of obese or overweight individuals and the current lack of efficacious, safe and well-tolerated weight-loss drugs. However, none of the emerging therapies are set to dominate the space owing to historical safety concerns that have fostered a cautious attitude among physicians and regulatory authorities, particularly in markets outside the United States.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Obesity finds that Orexigen/Takeda's Contrave will become the most widely used emerging therapy due to the fact it offers the best available balance of efficacy and safety among the competing therapeutic entities. A 3.0 mg formulation of Novo Nordisk's Victoza will become the sales leader over the 2012-2022 forecast period, owing to its premium price combined with physician familiarity and the additional metabolic benefits the drug provides. The U.S. launches of Vivus's Qsymia and Arena Pharmaceuticals/Eisai's Belviq in 2012 and 2013, respectively, have both been met with modest uptake, suggesting that historical safety issues associated with antiobesity agents still weigh on the minds of physicians. European and Japanese physicians will also have new treatments available from early in the forecast period, although they will continue to have fewer options from which to choose than their U.S. counterparts.

Decision Resources forecasts that the obesity drug market will grow more than fivefold over the next decade to ex
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
2. Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes
3. Emerging Drug Delivery Technologies, Profiles of Start-ups and Early-Stage Companies
4. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
6. Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons
7. CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
8. Bioabsorbable Stents - Global Strategic Business Report - 2013 Profiles 16 Companies inside the Market
9. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
10. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
11. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)...  PARI Respiratory Equipment has won a 2015 American Package ... by the FDA on December 2, is the first co-packaging ... ® Nebulizer for patients with cystic fibrosis. ... into this unique product offering of nebulized drug and device. ... use, we also wanted to convey that the components suit ...
(Date:6/3/2015)... PITTSBURGH , June 3, 2015 Mylan ... today announced that the Company will present at Goldman Sachs ... 9, 2015. The presentation is scheduled to begin at 4 ... parties can access a live webcast of the presentation via ... .   Mylan is a global pharmaceutical company ...
(Date:6/3/2015)... June 3, 2015  NxStage Medical, Inc. (Nasdaq: ... products , today announced data that home hemodialysis ... million gallons of water annually by transitioning just ... home hemodialysis with the NxStage® System One™.  Industry ... gallons of water per patient per week, whereas ...
Breaking Medicine Technology:Kitabis Pak Wins American Package Design Award 2Home Hemodialysis With NxStage System One Can Save California 221 Million Gallons of Water Annually 2
... , ABBOTT ... ABT ) announced today that the U.S. Food and Drug Administration ... company,s antiretroviral medication Norvir ® (ritonavir).  The new Norvir ... refrigeration, making it more convenient for patients.  The Norvir tablets and ...
... SUNNYVALE, Calif. , Feb 11 Pharmacyclics, Inc. (Nasdaq: ... December 31, 2009 . , Upon the completion of a ... 2009 , the company began recognizing revenue under GAAP from its collaboration ... Total revenue recognized under GAAP in our most recent quarter was ...
Cached Medicine Technology:Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 2Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 3Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 4Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 5Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 6Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 7Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 8Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 9Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 10Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 11Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 12Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets 13Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 2Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 3Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 4Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 5Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 6Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 7Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 8Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 9Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 10Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 11Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 12Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 13Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 14Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 15Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 16Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 17Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 18Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results 19
(Date:6/3/2015)... (PRWEB) June 03, 2015 Researchers at ... biomarkers for mesothelioma and say the tried-and-true marker mesothelin ... posted an article on the research. Click here ... University’s National Center for Asbestos Related Diseases say, even ... results, it is still preferable to fibulin-3 for identifying ...
(Date:6/3/2015)... Pittsburgh, PA (PRWEB) June 03, 2015 ... basis can cause discomfort in the back, neck, shoulders ... or other musculoskeletal injuries. In addition, recent research links ... a number of chronic diseases. Fortunately, three inventors from ... than sit at a desk. , They have developed ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 On Sunday, ... the world will gather in their local communities to ... of cities across the U.S. and abroad will hold ... bring attention to the ongoing challenges of cancer survivorship, ... cancer diagnosis can be fruitful, rewarding, and inspiring.,  , ...
(Date:6/3/2015)... 03, 2015 Fourroux Prosthetics, located at ... will celebrate its grand opening with a ribbon cutting ... prosthetic center of its kind in the area, Fourroux ... care and outcomes through use of patented advanced prosthetics ... CEO of Fourroux Prosthetics, states, “Our goal has always ...
(Date:6/3/2015)... are challenging and unpredictable times for traditional organizations across ... are rewriting the rules for business as we knew ... businesses to take on a more agile approach in ... On top of this there is a growing trend ... new innovation and approaches to business. , The manager ...
Breaking Medicine News(10 mins):Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 2Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 3Health News:Communities to Recognize Cancer Survivors, Raise Awareness on National Cancer Survivors Day® – Sunday, June 7 4Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2
... to turn back the clock on aging stem cells ... in a fracture every three seconds worldwide, according to ... the right signals could help aging stem cells act ... death and disability associated with a frail framework, Georgia ...
... WEDNESDAY, June 8 (HealthDay News) -- The U.S. Food and ... the popular statin Zocor because of an increased risk of ... This risk has been seen among some people taking 80 ... year of treatment, the agency said. In light of this, ...
... winter 2009-2010 was much more widespread than was previously realised, research ... year at the end of the H1N1 flu season showed that ... of the 44 per cent who tested positive had contracted swine ... flu, or had been vaccinated. The research, led by ...
... Randy Dotinga HealthDay Reporter , WEDNESDAY, June 8 (HealthDay ... may be available in the United States as soon as this ... for the scans to be of much help for those ... earlier diagnosis, which can be important to people who want to ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) -- Girls ... explain some cases of autism in families with no history ... a certain number of duplications or deletions of one or ... explained Dr. Christian Schaaf, an assistant professor in the department ...
... The University of Alabama at Birmingham has taken a ... patient care with its acquisition of the first cell-processing workstation ... States. Richard Marchase, Ph.D., vice president for Research ... history of breaking ground in the cell-therapy arena. We are ...
Cached Medicine News:Health News:Researchers work to turn back the clock on bone-producing stem cells 2Health News:Researchers work to turn back the clock on bone-producing stem cells 3Health News:Researchers work to turn back the clock on bone-producing stem cells 4Health News:FDA Places New Warning Label on Zocor 2Health News:FDA Places New Warning Label on Zocor 3Health News:Brain Scans to Spot Alzheimer's May Be Available This Year 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 3Health News:Girls May Be More Resistant to Autism Than Boys: Study 4Health News:UAB first in US with cell-processing workstation 2Health News:UAB first in US with cell-processing workstation 3
Reciprocating shaker specifically for platelet bags....
... quantitative determination of progesterone ... Progesterone EIA is ... of competitive binding between ... specimen and progesterone-HRP conjugate ...
... With the introduction of the innovative GenePaint ... a genome-wide scale is much easier. The ... tightly temperature-controlled manner all steps required for ... microscope slide formats. This includes fixing, staining, ...
... Labcold platelet incubators provide accurate and ... have incorporated all of the same ... are found in the Labcold BS ... levels of product security. An independent ...
Medicine Products: